How Blocking the Inflammatory Effects of C5a In Critically Ill COVID-19 Patients Can Lead to a Survival Benefit
Recorded On: 12/19/2023
Webinar Description:
This sponsored webinar will provide an overview of the Complement System and C5a Activation, the potential role of C5a in COVID-19 disease progression, and a review of the clinical data for a product recently FDA-authorized for emergency use in critically ill adult patients hospitalized with COVID-19.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided by InflaRX for this sponsored webinar.
Niels Riedemann, MD, PhD
Chief Executive Officer and Founder
InflaRX
Niels Riedemann, MD, PhD, is a co-founder and CEO of InflaRx. He has over 15 years of experience in biotech and 23 years of experience in complement immunology research, with more than 60 peer-reviewed scientific publications in highly ranked journals and several national and international accolades for his research and work. From 2009 to 2015, he served as Vice Director of Intensive Care Medicine at Friedrich Schiller University in Jena, Germany, where he led a 50-bed academic ICU unit. He received his medical training from Albert Ludwig University and Stanford University, worked as postdoctoral research fellow at the University of Michigan, and received his PhD. from Hannover Medical School. He is board certified general surgeon and intensive care physician. Dr. Riedemann serves as Co-Chair of the Health Politics working group of Bio-Deutschland and as a member of the board of trustees for the German Sepsis Foundation.